Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Related Articles by Review for PubMed (Select 21585328)

1.
2.

Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.

Gil-Mohapel JM.

CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x. Review.

PMID:
21501423
3.

Neuroprotective possibilities for Huntington's disease.

Emerich DF.

Expert Opin Biol Ther. 2001 May;1(3):467-79. Review.

PMID:
11727519
4.
5.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

6.

Development of novel therapies for Huntington's disease: hope and challenge.

Qin ZH, Wang J, Gu ZL.

Acta Pharmacol Sin. 2005 Feb;26(2):129-42. Review.

7.

Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM.

Int J Biol Sci. 2014 Sep 10;10(9):1024-38. doi: 10.7150/ijbs.9898. eCollection 2014. Review.

8.

[Huntington's disease: intracellular signaling pathways and neuronal death].

Humbert S, Saudou F.

J Soc Biol. 2005;199(3):247-51. Review. French.

PMID:
16471265
9.

Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Han I, You Y, Kordower JH, Brady ST, Morfini GA.

J Neurochem. 2010 Jun;113(5):1073-91. doi: 10.1111/j.1471-4159.2010.06672.x. Epub 2010 Mar 17. Review.

10.

Mouse models of Huntington's disease.

Menalled LB, Chesselet MF.

Trends Pharmacol Sci. 2002 Jan;23(1):32-9. Review.

PMID:
11804649
11.

Neuroprotective effects of psychotropic drugs in Huntington's disease.

Lauterbach EC.

Int J Mol Sci. 2013 Nov 15;14(11):22558-603. doi: 10.3390/ijms141122558. Review.

12.

Huntington's disease.

MacDonald ME, Gines S, Gusella JF, Wheeler VC.

Neuromolecular Med. 2003;4(1-2):7-20. Review.

PMID:
14528049
13.

Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.

Alberch J, Pérez-Navarro E, Canals JM.

Brain Res Bull. 2002 Apr;57(6):817-22. Review.

PMID:
12031278
14.

Prospects for neuroprotective therapies in prodromal Huntington's disease.

Chandra A, Johri A, Beal MF.

Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Review.

PMID:
24573776
15.

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

Nithianantharajah J, Hannan AJ.

Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Epub 2012 May 24. Review.

PMID:
22633949
16.

Huntington's Disease.

Finkbeiner S.

Cold Spring Harb Perspect Biol. 2011 Jun 1;3(6). pii: a007476. doi: 10.1101/cshperspect.a007476. Review.

17.

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.

PMID:
19909260
18.

The role of immunity in Huntington's disease.

Soulet D, Cicchetti F.

Mol Psychiatry. 2011 Sep;16(9):889-902. doi: 10.1038/mp.2011.28. Epub 2011 Apr 26. Review.

PMID:
21519341
19.

Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.

Lee CY, Cantle JP, Yang XW.

FEBS J. 2013 Sep;280(18):4382-94. doi: 10.1111/febs.12418. Epub 2013 Jul 31. Review.

20.

Hypothalamic and neuroendocrine changes in Huntington's disease.

Hult S, Schultz K, Soylu R, Petersén A.

Curr Drug Targets. 2010 Oct;11(10):1237-49. Review.

PMID:
20594177
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk